Interview with Dr. Rajesh Jain, Joint Managing Director, Panacea Biotec
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
Address: B-1 Extn./ A-27, Mohan Co-op. Industrial Estate, Mathura Road, New Delhi -110044, INDIA
,India
Tel: +91-11-26945270
Web: http://www.panaceabiotec.com/
Panacea Biotec is one of India’s leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey- June 2009) and is also amongst the top 50 pharmaceutical companies in India. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company’s state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with International Regulatory requirements like US-FDA, UK-MHRA, SAMCC and WHO-cGMP standards. Panacea Biotec has five dedicated research and development centers. The company has around 3200 employees including over 300 scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.
The product portfolio of the Company includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines.
The Indian biotechnology sector is quite particular. In spite of its young age, the industry has grown significantly in a very short time. In your view, where does the Indian…
As the founder and chairman of Alves Group, a key Indian player in medical devices with an extensive portfolio, Randolph Alves shares the challenges India needs to overcome to remain…
Dharmesh Shah, managing director of BDR Pharmaceuticals, a company with a strong expertise in oncology, intensive care, and other therapeutic areas, provides us with an insightful overview of the main…
For multinational companies, despite ‘pharmerging markets’ not holding the hype and allure they once did, India still stands as a land of opportunity for a variety of reasons. Novartis India…
Umang Vohra, managing director and global CEO of Indian pharma giant Cipla, discusses the company’s ambition to grow in both the domestic and emerging markets as well as the opportunities…
Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’…
Manni Kantipudi, CEO of GVK BIO, talks about the evolution of the company, which he took from USD 20 million to its current USD 120 million, its future, its strategic…
R.S. Subramanian, country manager and Sandeep Juneja, vice president – Sales and Marketing, DHL Express India, explain why the world’s leading express logistics company is a trusted and accountable service…
A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB)…
A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty…
Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized…
Satish Kumar Singh (managing director) & Shashi Shekhar Kumar (vice president International Business) from M/s Cachet Pharmaceuticals Pvt. Ltd., discuss their success with special reference to marketing, distribution and operating…
A pioneer of the biotechnology industry in India and the head of the country’s leading biotechnology enterprise, Kiran Mazumdar-Shaw, discusses the recent US FDA approval of Ogivri™, the first biosimilar…
See our Cookie Privacy Policy Here